Literature DB >> 21753725

Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.

Teresa Leung, Julie Lokan, Paul Turner, Carole Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21753725     DOI： 10.1097/PAT.0b013e328348fecc

Source DB:  PubMed          Journal:  Pathology        ISSN： 0031-3025            Impact factor:   5.306


× No keyword cloud information.
  4 in total

Review 1.  Thrombopoietin receptor agonists in primary immune thrombocytopenia.

Authors:  Deborah Siegal; Mark Crowther; Adam Cuker
Journal:  Semin Hematol       Date:  2013-01       Impact factor: 3.851

2.  Myelofibrosis associated with romiplostim treatment in a patient with immune thrombocytopenia.

Authors:  Maria Fernanda Gonzalez; Jonathan King Freeman
Journal:  Case Rep Hematol       Date:  2012-04-01

Review 3.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

Review 4.  Dualistic role of platelets in living donor liver transplantation: Are they harmful?

Authors:  Chen Liang; Kazuhiro Takahashi; Kinji Furuya; Nobuhiro Ohkohchi; Tatsuya Oda
Journal:  World J Gastroenterol       Date:  2022-03-07       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.